Sangamo Therapeutics (SGMO) Aktievy
Sangamo Therapeutics, Inc, ett företag inom genomisk medicin i klinisk fas, fokuserar på att omvandla vetenskap till läkemedel som förändrar livet för patienter och familjer som drabbats av allvarliga sjukdomar i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
SGMO Community Fair Values
Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sangamo Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$0.14 |
| 52 veckors högsta | US$0.78 |
| 52 veckors lägsta | US$0.12 |
| Beta | 1.5 |
| 1 månads förändring | -48.10% |
| 3 månaders förändring | -74.79% |
| 1 års förändring | -81.46% |
| 3 års förändring | -89.93% |
| 5 års förändring | -98.72% |
| Förändring sedan börsintroduktionen | -99.10% |
Senaste nyheter och uppdateringar
SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity Fears
Analysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future Upside
Analysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).Recent updates
SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity Fears
Analysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future Upside
Analysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).SGMO: Fabry Gene Therapy Filing And Kidney Endpoint Will Drive Upside
Analysts have adjusted their price target on Sangamo Therapeutics to $1.25, with the change based on updated views on discount rate, revenue growth, profit margin, and future P/E assumptions, even though the fair value estimate itself remains $1.25. What's in the News Sangamo started a rolling submission of a Biologics License Application to the FDA for isaralgagene civaparvovec (ST-920), an investigational one time gene therapy for adults with Fabry disease, and has submitted the preclinical and clinical modules for review (Key Developments).SGMO: Accelerated Approval Pathway On Kidney Data Will Drive Bullish Upside
Analysts have set their price target for Sangamo Therapeutics at $1.25, based on updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while the fair value estimate remains unchanged at $1.25. What's in the News Sangamo reported detailed data from the registrational Phase 1/2 STAAR study of its gene therapy candidate isaralgagene civaparvovec (ST 920) for Fabry disease.SGMO: Accelerated Approval On Kidney Function Data Will Drive Bullish Thesis
Analysts have maintained their average price target for Sangamo Therapeutics at $1.25. This reflects minor adjustments to their models, including slightly different assumptions for discount rate, revenue growth, profit margin, and forward P/E, rather than a change in their overall view.SGMO: Accelerated Approval Using EGFR Slope Will Support Bullish Outlook
Analysts have nudged their fair value estimate for Sangamo Therapeutics higher to $1.25 from $1.00, citing updated assumptions around revenue growth, profit margins, discount rates and a higher future P/E multiple. What's in the News Sangamo Therapeutics completed a follow on equity offering totaling approximately US$24.8 million, issuing 35,190,292 shares of common stock at US$0.4719 per share and 17,787,033 pre funded warrants at US$0.4619 per warrant (Key Developments).Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Feb 03
SGMO: Accelerated Approval Pathway Will Drive Upside Despite Downgrade Through 2026
Narrative Update Analysts have cut their price target on Sangamo Therapeutics from US$5 to US$1, citing the recent downgrade to Equal Weight and a wait for more clarity on a potential Fabry deal, despite the FDA reaffirming an accelerated approval path and the company extending its cash runway into Q1 2026. Analyst Commentary Recent research paints a mixed picture for Sangamo Therapeutics, with the lower price target and rating downgrade balanced against some supportive clinical and balance sheet signals.SGMO: Accelerated Approval Path Using EGFR Slope Will Drive Future Upside
Analysts have trimmed their 12 month price target on Sangamo Therapeutics to US$1 from US$5, citing a wait and see stance on Fabry deal clarity and the current cash runway into Q1 2026, despite the reaffirmed accelerated approval path using eGFR slope. Analyst Commentary Bearish analysts are signaling a more cautious stance on Sangamo Therapeutics after the recent Q3 update, with the sharp cut in the 12 month price target standing out as a key marker of reduced confidence.SGMO: Accelerated Approval Pathway And Extended Runway Will Support Upside Through 2026
Analysts have modestly reduced their price target on Sangamo Therapeutics to $1 from $5, citing a more cautious stance as they await greater clarity on potential Fabry partnership developments, despite the extended cash runway and reaffirmed accelerated approval pathway. Analyst Commentary Analysts note that the downgrade and lower price target reflect a shift toward a more balanced risk reward profile, with recent catalysts prompting both supportive and cautious views on Sangamo Therapeutics.SGMO: Accelerated Approval Pathway Is Expected To Drive Upside Through 2026
Analysts have lowered their price target on Sangamo Therapeutics from $5.00 to $1.00 per share, citing a more cautious stance as they await greater clarity on a potential Fabry partnership, despite an extended cash runway and a reaffirmed accelerated approval path. Analyst Commentary Analysts are reassessing Sangamo Therapeutics with a more balanced view, emphasizing both the company’s de-risked regulatory path and the uncertainties that could weigh on execution and valuation.SGMO: FDA Accelerated Pathway Will Extend Bullish Momentum Into 2026
Analysts have lowered Sangamo Therapeutics’ price target from $5 to $1, citing uncertainty around future partnership deals. This is despite recent regulatory updates and an extended cash runway.Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive
Nov 23SGMO: FDA Approval Path Will Drive Bullish Outlook Into 2026
Analysts have lowered their price target for Sangamo Therapeutics from $5 to $1. They cited a cautious outlook, pending greater clarity on a Fabry collaboration and updated guidance following the company's latest quarterly report.There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise
Oct 07Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth
Sep 23FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
The sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10. What's in the News CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
Sangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62. What's in the News Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jul 24
Neurology IND And Fabry Agreements Will Transform Treatment
Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements.Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Mar 04Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%
Dec 08Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts
Nov 20What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Oct 23Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Oct 21There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Aug 03Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Jul 23Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Aktieägarnas avkastning
| SGMO | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -29.0% | -2.5% | 0.8% |
| 1Y | -81.5% | 26.8% | 27.7% |
Avkastning vs industri: SGMO presterade sämre än US Biotechs branschen som gav 26.8 % under det senaste året.
Avkastning vs Marknaden: SGMO presterade sämre än US marknaden som gav 27.7 % under det senaste året.
Prisvolatilitet
| SGMO volatility | |
|---|---|
| SGMO Average Weekly Movement | 20.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabil aktiekurs: SGMO s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: SGMO s veckovolatilitet ( 20% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1995 | 142 | Sandy Macrae | www.sangamo.com |
Sangamo Therapeutics, Inc, ett genomikmedicinskt företag i klinisk fas, fokuserar på att omvandla vetenskap till läkemedel som förändrar livet för patienter och familjer som drabbats av allvarliga sjukdomar i USA. Bolagets produktkandidater i klinisk fas är ST-920, en genterapiproduktkandidat som befinner sig i klinisk fas 1/2-studie för behandling av Fabrys sjukdom, småfiberneuropati för kronisk neuropatisk smärta och prionsjukdom; klinisk fas 1/2-studie för att utvärdera säkerhet och tolerabilitet för den undersökta genetiskt modifierade cellterapin TX200 hos patienter som genomgår en njurtransplantation SB-525, en produktkandidat för genterapi, som befinner sig i klinisk fas 3-studie för behandling av måttligt svår till svår hemofili A; giroctocogene fitelparvovec, en fas 3-studie för att utvärdera den kliniska effekten och säkerheten av genterapi med giroctocogene fitelparvovec hos vuxna män med måttligt svår eller svår hemofili A. Sangamo Therapeutics, Inc. har samarbetsavtal och strategiska partnerskap med Genentech, Inc; Astellas Gene Therapies, Inc; Capsid Delivery License Agreement med Eli Lilly and Company; Alexion Pharmaceuticals, Inc - ALS och Frontotemporal Lobar Degeneration; Takeda - Huntingtons sjukdom; och andra områden, såsom växtodling och forskningsreagenser, inklusive produktion av transgena djur och cellinjeteknik med Corteva AgriScience och Open Monoclonal Technology, Inc. Bolaget var tidigare känt under namnet Sangamo BioSciences, Inc. och bytte namn till Sangamo Therapeutics, Inc. i januari 2017.
Sangamo Therapeutics, Inc. Sammanfattning av grunderna
| SGMO grundläggande statistik | |
|---|---|
| Börsvärde | US$49.38m |
| Vinst(TTM) | -US$122.93m |
| Intäkter(TTM) | US$39.55m |
Är SGMO övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SGMO resultaträkning (TTM) | |
|---|---|
| Intäkter | US$39.55m |
| Kostnad för intäkter | US$112.67m |
| Bruttovinst | -US$73.12m |
| Övriga kostnader | US$49.81m |
| Intäkter | -US$122.93m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.30 |
| Bruttomarginal | -184.87% |
| Nettovinstmarginal | -310.81% |
| Skuld/egenkapitalförhållande | 0% |
Hur har SGMO utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/01 08:43 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Sangamo Therapeutics, Inc. bevakas av 16 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |
| John Newman | Citizens JMP Securities, LLC |